Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.65 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 2/20 | 0.57 |
| ▸ | NPY2R | P49146 | 2/20 | 0.57 |
| ▸ | NPY4R | P50391 | 2/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30380084 | 1.00 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL29408676 | 1.00 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL31514538 | 1.00 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL30276213 | 0.97 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL30276250 | 0.97 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL11410468 | 0.97 | IL23R (0.64) | IL23RUTS2RGHSRKISS1R | |
| SCHEMBL11410421 | 0.97 | IL23R (0.64) | IL23RUTS2RGHSRKISS1R | |
| SCHEMBL31091578 | 0.97 | IL23R (0.66) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL29938267 | 0.96 | IL23R (0.61) | IL23RUTS2RGHSRKISS1R | |
| SCHEMBL29938179 | 0.96 | IL23R (0.61) | IL23RUTS2RGHSRKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215925-B | Somatostatin type 2 receptor inhibitor, radionuclide complex thereof, preparation method and application | 上海益泰医药科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| WO-2025043563-A1 | PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF | 主流源生物科技(上海)有限公司 | 2025-03-06 | — | — | WO | claimed |
| CN-118201644-A | Ligand compounds comprising chelating groups as bridging groups | 慕尼黑工业大学 | 2024-06-14 | — | — | CN | claimed |
| EP-4380629-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2024-06-12 | — | — | EP | claimed |
| WO-2023012282-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2023-02-09 | — | — | WO | claimed |
| EP-3965751-B1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM ISOTOPE TECH MUNICH SE (DE) | 2022-12-28 | — | — | EP | claimed |
| CN-115215925-A | Somatostatin type-2 receptor inhibitor and radionuclide complex thereof, and preparation method and application thereof | 上海益泰医药科技有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-122074048-A | Methods of treating cancer | 诺华股份有限公司 | 2026-05-22 | — | — | CN | disclosed |
| EP-4619411-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-09-24 | — | — | EP | disclosed |
| CN-115215925-B | Somatostatin type 2 receptor inhibitor, radionuclide complex thereof, preparation method and application | 上海益泰医药科技有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-120129690-A | Dual receptor targeted radioligands and uses thereof | 辐联科技香港有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4561968-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | Technische Universität München (DE) | 2025-06-04 | — | — | EP | disclosed |
| US-20250114487-A1 | COMBINATION TREATMENT OF TUMORS | THE UNIVERSITY OF CHICAGO | 2025-04-10 | — | — | US | disclosed |
| CN-116251200-A | 177 Use of Lu-DOTATATATE in small cell lung cancer | 北京先通国际医药科技股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023012282-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | disclosed |
| CN-115215925-A | Somatostatin type-2 receptor inhibitor and radionuclide complex thereof, and preparation method and application thereof | 上海益泰医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114364405-A | Prostate Specific Membrane Antigen (PSMA) inhibitors as diagnostic agents and radionuclide therapeutics | 五一一制药股份有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114126654-A | Para-aminohippuric acid (PAH) as a kidney protective substance | 同位素技术慕尼黑有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-108473538-B | SSTR targeting conjugates and particles and formulations thereof | 塔弗达治疗有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114487-A1 | COMBINATION TREATMENT OF TUMORS | ESRRB, ESRRA, ESRRG | IL23R 955/4885UTS2R 696/4885GHSR 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.